- Dr. Countouriotis brings nearly two decades of leadership experience across pharmaceutical and biotechnology companies, leading the development of multiple oncology programs through approval

- Michael Rosenzweig, DVM, Ph.D., appointed Executive Vice President, Portfolio Strategy and Product Development

SAN DIEGO & PHILADELPHIA, October 12, 2022--(BUSINESS WIRE)--Capstan Therapeutics, Inc., a biotechnology company dedicated to developing and delivering precise in vivo cell engineering to patients, today announced the appointment of experienced biotechnology leader Athena Countouriotis, M.D., as Board Chair and Michael Rosenzweig, DVM, Ph.D., as Executive Vice President, Portfolio Strategy and Product Development.

"We are thrilled Athena will be leading our Board and providing senior counsel to our team from her deep experience leading the development of multiple development programs to approval. Her strategic insights will be invaluable to us as we make continued progress towards our goal of delivering precise in vivo cell engineering to patients," said Laura Shawver, Ph.D., President and Chief Executive Officer of Capstan Therapeutics. "We are further pleased to welcome Michael to our expanding leadership team as we harness the breakthrough scientific discoveries of our founders to advance a robust pipeline of therapeutic candidates for oncology, autoimmune disease, blood disorders and fibrosis."

Dr. Countouriotis most recently served as President and Chief Executive Officer of Turning Point Therapeutics until its $4.1 billion sale to Bristol Myers Squibb in August 2022. Prior to her role as President and CEO, she was Chief Medical Officer at several biotechnology companies, including Turning Point, Adverum Biotechnologies, Halozyme Therapeutics and Ambit Biosciences. At Ambit she helped lead the company’s initial public offering and was responsible for the clinical development of quizartinib until the company’s acquisition by Daiichi Sankyo in November 2014. Earlier in her career, Dr. Countouriotis led various clinical development organizations within Pfizer and Bristol Myers Squibb for oncology therapeutics including Sutent ®, Mylotarg™, Bosulif ® and Sprycel ®. She also serves on the Board of Directors of Iovance Biotherapeutics, Passage Bio, Recludix Pharma and Leal Therapeutics.

"Capstan’s potential to invent novel clinical paradigms for patients represents an exciting new chapter for the fields of cell therapy, gene editing and mRNA therapeutics. From broadening the indications each of these technologies can address, to streamlining manufacturing, to delivering these medicines to patients in an earlier-line treatment settings, Capstan’s in vivo cell engineering approach holds tremendous promise to transform clinical practice and overcome many of the hurdles the field currently faces," said Dr. Countouriotis. "I am thrilled to be working with Laura, her inspiring team and Capstan’s esteemed founders, to rapidly advance this pioneering area of medicine."

In addition to Dr. Countouriotis’ appointment, Michael Rosenzweig, DVM, Ph.D., joins Capstan’s leadership team as Executive Vice President, Portfolio Strategy and Product Development to lead the selection and advancement of Capstan’s therapeutic programs. Dr. Rosenzweig most recently served as an Entrepreneur in Residence at RA Ventures. He has more than two decades of experience across pharmaceutical and biotechnology companies, including leading oncology and immunology discovery at Merck Research Labs as well as in leadership roles at Immunext and ToleRx. He is a member of the Board of Directors of Bright Peak and the Scientific Advisory Board of Avilar.

"Capstan’s technology represents a significant new step forward in the effort to unlock the full potential of mRNA-based medicine and to deliver new applications of this technology for patients across a wider range of diseases," said Dr. Rosenzweig. "I am thrilled to be joining this team at this exciting time, to continue to advance Capstan’s programs across oncology, autoimmune disease, blood disorders, fibrosis and stem cell editing."

About Capstan (www.capstantx.com) Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need. The core technology comprises targeted Lipid Nanoparticles (tLNPs) to enable engineering or ablation of pathogenic cells in the body. The company is combining the power of cell therapy with the precision of genetic medicines to develop new treatment options for patients for oncology, fibrosis, inflammation-related diseases, and monogenic blood disorders. The Company is co-founded by pioneers in the field of CAR-based immunotherapy, nucleic acid drug delivery, tLNPs, and regenerative medicine, including experienced industry leaders, as well as academic faculty members from the University of Pennsylvania. Launched in 2022 with $165 million in Series A and seed financing from Novartis Venture Fund, OrbiMed, RA Capital, Vida Ventures, Polaris Partners, Alexandria Venture Investments, Pfizer Ventures, Leaps by Bayer, Eli Lilly and Company and Bristol Myers Squibb, Capstan has a bicoastal presence with operations in San Diego, CA and Philadelphia, PA. For more information, please visit www.capstantx.com and follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221012005195/en/

Investors: Patrick Jeanmart Chief Financial Officer Capstan Therapeutics pjeanmart@capstantx.com

Media: Rebecca Spalding Ten Bridge Communications +1 646-509-3831 rebecca@tenbridgecommunications.com

The 86-year-old investing legend has spoken. You may want to pay attention.

Stock splits have been all the rage this year as several prominent companies have decided to go down this path to lower their share prices and boost the demand among retail investors at a time when the broader market has been in sell-off mode, but even this move hasn't given them reprieve on the stock market. Palo Alto Networks (NASDAQ: PANW), for instance, announced a three-for-one stock split on Aug. 22. Shares of the cybersecurity specialist shot up following the announcement, but they have lost momentum since thanks to the Federal Reserve's hawkish nature that has been weighing on the stock market this year.

At 92 and 86 years of age, respectively, Warren Buffett and Carl Icahn are two of the greatest living investors  -- and both are still at it! In fact, these two seniors have been quite active this year, especially around oil giant Occidental Petroleum (NYSE: OXY). On the flip side, Warren Buffett has been buying Occidental shares hand over fist throughout the year, scooping up over 20% of the American oil driller.

Currently, AT&T sports a high 7.4% dividend yield, which means the company will pay an estimated 7.4% of its stock price to shareholders each year. This number constantly fluctuates because it is calculated using the annual dividend payout divided by the stock price. The yield rises if the dividend goes up and the stock price stays the same.

(Bloomberg) -- Tesla Inc. shares tumbled about 50% from their all-time high, amid a broader selloff in the US stock market that has hit growth and technology companies especially hard. Most Read from BloombergNATO-China Tension Over Ukraine Flares at Conference in IcelandRolex Prices to Drop Further as Supply Surges: Morgan StanleyDiesel Hits Chaos Mode in Fresh Blow for Global EconomyThe electric vehicle-maker’s shares closed down 7.6% to $204.99 on Friday, taking its market capitalization to $

Both companies have seen their share price fall, but that doesn't mean Apple or Amazon wouldn't be interested at the right number.

If you only read headlines, you might think that Beyond Meat's (NASDAQ: BYND) Friday press release announcing that the plant-based "meat" producer is shooting to be cash flow positive by the second half of 2023 was a piece of good news. Demand for plant-based meat has weakened, with consumers moving away from the category amid sky-high inflation.

Wall Street in the week ahead will turn to quarterly results from companies like streaming giant Netflix Inc. and electric-vehicle maker Tesla Inc.

Being patient doesn't always pay off.

These diversified natural-resource giants have solid balance sheets, earnings, and dividends. All that they need is a rebound in commodity prices.

In this article, we will take a look at 11 of the best financial services stocks to buy now. If you want to see some more of the 11 best financial services stocks to buy, go directly to 5 Best Financial Services Stocks to Buy Now. Financial services stocks provide many different services to their […]

The economist warned in 2006 that the U.S. housing bust would cause a financial crisis. Now he has a new economic doomsday prediction, and it isn't pretty.

Investors searching for safe places to store some cash amid high inflation and volatile markets have options. In continuation of Yahoo Finance's series 'What to do in a bear market', we asked the experts where to park money safely, amid high inflation.

The research firm came up with a list of the best companies to own based on ones to which Morningstar analysts assign a wide moat.

A new rally attempt is already struggling. Netflix and Tesla earnings loom. Shockwave is a stock to watch.

Investors seemingly can’t stop trying to pick a stock market bottom, no matter how bad the news—and it continues to backfire. The initial response was exactly what you’d expect—the traded down as much as 2.4%—but then it started rallying…and rallying. A rise in inflation expectations that showed up in the University of Michigan’s consumer sentiment survey on Friday pushed Treasury yields to their highest levels since 2008.

The premium being paid by Kroger (KR) for the company's merger values ACI closer to its 52-week highs and could eventually give the stock another short-term catalyst. With or without the merger, ACI stock may be worth investors' consideration as its growth outlook has become more intriguing.

With the S&P 500 index firmly in bear market territory, down 25% year-to-date, investors are rightly nervous about what it means for stocks. As Warren Buffett once said, be fearful when others are greedy, and greedy when others are fearful. As long as investors have an appropriate investment horizon -- 10 years is usually good -- they should not fear bear markets, but look forward to them eagerly as a chance to buy good companies at discounted prices.

The U.S. Treasury Department put an item on its agenda Friday to start talking with primary dealers about the potential for it to buy back some of its older debt to help keep markets functioning smoothly.

The Nasdaq Composite Index has tumbled more than 35% from its recent peak, putting it in a deep bear market. With their share prices tumbling, they trade at much lower valuations. Because of that, investors could score big gains by taking advantage of the sell-off and holding through the eventual recovery.